



ZENITH DRUGS LIMITED
(Formerly - Zenith Drugs Private Limited)

CONTACT US:



www.zenithdrugs.com



info@zenithdrugs.com



+91 93291 45074

CIN: U24231MP2000PLC014465



Plant Add.- 72/5&72/1, 72/3, 74/1/1, 75/1/1 Muradpura (Orangpura),
Dhar Road, Near Kalaria, INDORE, PIN-453001 (MP) INDIA



Registered Office Address - K. No. 72/5, Village Muradpura, Depalpur, Indore, Madhya Pradesh - 453001

March 15, 2024

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C-1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051.
Symbol: ZENITHDRUG

Dear Sir,

Sub: Clarification on significant movement in the price of security across Exchanges in the recent past - NSE Letter Ref. No.: NSE/CM/Surveillance/14029 dated March 14, 2024

This is with reference to your emailed letter Ref. No.: NSE/CM/Surveillance/14029 dated March 14, 2024, seeking clarification on the significant movement in the price of equity shares of Zenith Drugs Limited across Exchanges in the recent past. A copy of the above letter is enclosed herewith.

In this regard, we would like to inform you that the Company has made all the necessary disclosures in a timely and accurate manner in conformity with the principles governing disclosures and obligations in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 from time to time.

The Company has not withheld any material information / event that in our opinion would have a bearing on the price/volume behaviour in our shares. The Company will continue to inform the stock exchanges about any price sensitive information as required under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 from time to time.

Accordingly, the significant movement observed in the price of our shares across Exchanges in the recent past is purely market driven.

We hope you will find the clarification in order and request you to take the same on record.

Thanking you,
Yours faithfully,

For Zenith Drugs Limited

SANDEEP BHARDWAJ
Digitally signed by
SANDEEP BHARDWAJ
Date: 2024.03.15
10:47:04 +05'30'

Sandeep Bhardwaj
Managing Director & Chief Financial Officer
DIN: 00539347

Encl.: As above



National Stock Exchange Of India Limited

Ref. No.: NSE/CM/Surveillance/14029

March 14, 2024

The Company Secretary,
Zenith Drugs Limited.

Dear Sir/Madam,

Sub: Movement in Price

We have noted a significant movement in the price of your security across Exchanges, in the recent past.

Please note that as per Regulation 30 of the SEBI (LODR) Regulations, 2015, all listed companies are required to intimate to the Exchange all the events, information etc that have a bearing on the operation/performance of the company which include all price sensitive information, etc. In addition, all listed companies are also required to furnish to the Exchanges on request, such information concerning the company as may be reasonably required.

In view of the above and with a view to ensure that investors have latest relevant information about your company, you are requested to provide us with any information /announcement (including impending announcement) which in your opinion may have a bearing on the price / volume behavior in the scrip.

You are therefore advised to provide your response in respect of the above to the Exchange immediately on or before March 15, 2024 11.00 am by submission through NEAPS. For any further clarification, please reach us on surveillance@nse.co.in.

Please note that any information received from you in this regard would be disseminated to the market.

We are looking forward to receiving your mail/ submission through NEAPS (Compliance à News Clarification).

Thanking you.

Yours faithfully,

For National Stock Exchange of India Ltd.

Binoy Yohannan
Associate Vice President
Surveillance